Filter
1
FeaturedActive & Responsive

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

for
Solid Tumor
Location: Boston MA, New Haven CT, The Bronx NY, Montreal,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT06619587

Phase1, Recruiting
Featured

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

for
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma,
Location: San Antonio TX
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06084481

Phase1, Recruiting
Featured

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

for
Neoplasms
Location: New Haven CT, Toronto, Sarasota FL, Houston TX,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06884618

Phase1, Recruiting
Active & Responsive

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

for
Solid Tumor
Location: New York NY, Philadelphia PA, Washington D.C. DC,
Sponsor: Biohaven Therapeutics Ltd.

Sex: All

Age: 18+

Code: NCT06384807

Phase1, Phase2, Recruiting
Active & Responsive

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

for
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Alterome Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06835569

Phase1, Recruiting

Interested in new solid tumor trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06682793

Phase1, Phase2, Recruiting
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase1, Recruiting
Active & ResponsiveNew

REC-7735 in Participants With Solid Tumors

for
Solid Tumors
Location: Grand Rapids MI
Sponsor: Recursion Pharmaceuticals Inc.

Sex: All

Age: 18+

Code: NCT07819136

Phase1, Phase2, Recruiting
Active & ResponsiveNew

A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3

for
Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Location: Fairfax VA, Sarasota FL, Houston TX, San Antonio TX
Sponsor: Myricx Pharma Limited

Sex: All

Age: 18+

Code: NCT07807241

Phase1, Recruiting
Active & Responsive

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

for
Advanced Solid Tumor
Location: East Providence RI, Charleston SC, Huntersville NC,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT06750185

Phase1, Phase2, Recruiting
Active & Responsive

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

for
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Location: Fairfax VA, Charleston SC, Detroit MI, Houston TX,
Sponsor: A2A Pharmaceuticals Inc.

Sex: All

Age: 18+

Code: NCT06136884

Phase1, Recruiting
Active & Responsive

FOG-001 in Locally Advanced or Metastatic Solid Tumors

for
Cancer, Colorectal Cancer, Solid Tumor,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: Parabilis Medicines, Inc.

Sex: All

Age: 18+

Code: NCT05919264

Phase1, Phase2, Recruiting
Active & Responsive

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer,
Location: New Haven CT, Lake Success NY, New York NY, Fairfax VA,
Sponsor: Cogent Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07361562

Phase1, Recruiting
Active & Responsive

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

for
Solid Tumor, Adult, Colorectal Cancer,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT04981119

Recruiting
Active & Responsive

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

for
Solid Tumor
Location: Canton OH, Cleveland OH
Sponsor: Lamassu Bio Inc

Sex: All

Age: 18+

Code: NCT06578624

Phase1, Phase2, Recruiting
Active & Responsive

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

for
Advanced Solid Tumor
Location: Fairfax VA, Grand Rapids MI, Nashville TN, Dallas TX,
Sponsor: Ipsen

Sex: All

Age: 18+

Code: NCT06833008

Phase1, Phase2, Recruiting
Active & Responsive

PAS-004 in Patients With Advanced Solid Tumors

for
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Location: Fairfax VA, Irving TX, San Antonio TX
Sponsor: Pasithea Therapeutics Corp.

Sex: All

Age: 18+

Code: NCT06299839

Phase1, Recruiting
Active & Responsive

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06066424

Phase1, Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06051695

Phase1, Phase2, Recruiting
Active & Responsive

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

for
Solid Tumor, KRAS Mutation-Related Tumors
Location: Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 18+

Code: NCT05661201

Phase1, Recruiting